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1. Introduction 
Diabetes mellitus type 1 is the most common endocrine metabolic disorder in childhood and 
adolescence. In this condition there is an absolute insulin deficiency secondary to 
progressive destruction of pancreatic beta cells, causing severe alterations in the metabolism 
of all essential elements (carbohydrates, lipids and proteins). 
The most obvious alteration is chronic hyperglycemia, which is essential to diagnose the 
disease, and moreover, is the main responsible of many vascular and neurological 
complications that diabetic patients may develop long-term. 
In the development of diabetes mellitus type 1 involving both genetic and environmental 
factors. The traditional concept is that environmental factors may act as triggers of the 
immune response against ┚ of Langerhans cell phenotype in a genetically predisposed to the 
development of diabetes mellitus type 1. 
Autoimmune diseases are syndromes caused by activation of T cells or B or both, without 
evidence of other causes such as infection or cancer. When dendritic cells expressing self-
antigens in the context of HLA molecules stimulate peripheral T cells, they do so that they 
remain alive but anergic, no response until they contact a dendritic cell with multiple 
moleculescostimulatory expressing microbial antigens. 
Although many autoinmumnes diseases characterized by abnormal production of 
pathogenic autoantibodies, most of it is caused by an overreaction, combined T and B cells. 
In animal models of type 1 diabetes mellitus have demonstrated the high expression of 
MAdCAM-1 and GlyCAM-1 on HEV (high endothelial venules) of the inflamed pancreatic 
islets and the treatment of animals with inhibitors of the L-function selectin and ┙4 integrin, 
blockeddevelopment of type 1 diabetes mellitus. 
The American Diabetes Association divides the type 1 diabetes mellitus in two subgroups: 
1A is the result of autoimmune destruction of beta cells and the 1B subtype, which do not 
immunomarkers indicating a destructive autoimmune process of beta cellspancreas. 
However develop insulin deficiency by unidentified mechanisms and are prone to ketosis. It 
has been a predominance of African Americans and Asians in the 1B subtype. 
Genetic studies have shown that it is an inherited disease with polygenic trait. Genome wide 
studies have indicated the presence of at least 20 chromosomal regions that may contribute 
to genetic predisposition to type 1 diabetes mellitus. The most important genes that 
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influence susceptibility to type 1 diabetes are located in the HLA complex located on the 
short arm of chromosome 6 (6p21.3). 
The HLA-DQ is the locus that confers the major genetic susceptibility to develop type 1 
diabetes in humans. DQ molecules have two chains, alpha and beta, encoded by the DQA 
and DQB genes. Susceptibility to type 1 diabetes mellitus has been described by combining 
alpha-beta chains with no amino acid aspartic acid at position 57 of beta chain (DQB1*0302 
linked to DR4 and DQB1*0201 linked to DR3) and the presence of the amino acid arginine at 
position 52 of the alpha chain (DQA1*0301 linked to DR4 and DQA1*0501 linked to DR3). 
Based on these findings have been described both genotypes DQA/DQB disease associated 
with DQA1*0501/DQB1*0201 and DQA1*0301/DQB1*0302, which is more specific than 
DR3/DR4 genotype. 
Although other types of islet cells and ┙ cells (glucagon producing), delta cells (somatostatin 
producing) cells or PP (pancreatic polypeptide-producing) are functionally and 
embryologically similar to beta cells and express the most same. These proteins, inexplicably 
are free of autoimmune process. 
From the pathological standpoint, the cells of the pancreatic islets are infiltrated by 
lymphocytes (a process called insulitis). After the destruction of beta cells, the inflammatory 
process forwards, the islets are atrophic and disappear immunomarkers. 
Insulitis studies in humans and in animal models of type 1 diabetes mellitus (NOD mouse 
and BB rat) have identified the following abnormalities in both humoral branch as in the 
immune system cells: 
1. Autoantibodies against cell islet. 
2. Activated lymphocytesin islets, peripancreatic lymph nodes and widespread 
circulation. 
3. T lymphocytes that proliferate when stimulated with islet proteins. 
4. Release of cytokines within the insulitis. 
The beta cells appear to be particularly vulnerable to the toxic effect of some cytokines 
(tumor necrosis factor), interferon gamma and interleukin 1. Precise mechanisms are 
unknown the death of beta cells, but may involve formation of nitric oxide metabolites, 
apoptosis and direct cytotoxic effects of CD8+ T cells. It is believed that the destruction 
process does not involve autoantibodies against islet cells, since these antibodies do not 
react in general to the surface of islet cells and are capable of transferring diabetes mellitus 
in animals. 
Among islet molecules that are targets of the autoimmune process are insulin, glutamic acid 
decarboxylase (glutamic acid decarboxylase, GAD), the biosynthetic enzyme of the 
neurotransmitter gamma aminobutyric acid (gamma-aminobutyric acid,GABA), ICA-
512/IA-2 (with homology to tyrosine phosphatases, and fogrina (protein in secretory 
granules of insulin). Other less precisely defined autoantigens are islet ganglioside and 
carboxypeptidase H. Except none of the insulin-specific autoantigens are beta cells, which 
makes us wonder how these are destroyed selectively. 
Current theories favor the onset of an autoimmune process directed against beta cell 
molecule, which then spreads to other islet molecules as the autoimmune process destroys 
the beta cells and creates a series of secondary autoantigens. Beta cells of individuals with 
type 1 diabetes mellitus do not differ from the beta cells of normal people, because the 
transplanted islets are destroyed by the recurrence of autoimmune process of type 1 
diabetes mellitus. 
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Autoantibodies against islet cells (ICA) is a combination of several different antibodies 
directed against islet molecules such as GAD, insulin, IA-2/ICA-512 and islet ganglioside 
and serve as a marker of the autoimmune process of type 1 diabetes mellitus. The 
determination of the ICA may be useful to classify as type 1 diabetes mellitus and 
nondiabetic individuals identify risk. The ICA is present in most (> 75%) of individuals 
newly diagnosed with type 1 diabetes mellitus in a significant minority of diabetics newly 
diagnosed type 2 (5-10%) and sometimes, in pregnant women with gestational diabetes ( 
<5%). 
In 3-4% of first-degree relatives of individuals with type 1 diabetes mellitus ICA exist. Along 
with the presence of a disorder of insulin secretion in the proof of intravenous glucose 
tolerance predict a 50% higher risk of developing type 1 diabetes mellitus in the next 5 years. 
Without this disorder of insulin secretion, the presence of ICA predicts a five-year risk 
<25%. After this it follows that the risk of a first degree relative of type 1 diabetes mellitus is 
low. Today no approved treatment to prevent development of type 1 diabetes mellitus, so 
the detection of ICA in non-diabetic population has not been established as screening. 
There is another theory that talks about environmental factors as triggers of the autoimmune 
process in genetically vulnerable patients, but it is difficult to find an environmental trigger, 
since the event may precede by several years the development of the disease. Among the 
hypothetical environmental triggers include viruses (coxsackie and rubella), proteins early 
exposure to cow's milk and nitrosoureas. 
A major advance would get delay or prevent diabetes, there have been some intervention in 
animal models, whose main objective has been the immune system (immunosuppression, 
selective deletion of T cell subsets, immune tolerance induction to proteinsisland), while 
others avoid the death of islet cells by blocking the cytotoxic cytokines or increasing islet 
resistance to the destruction process. 
Type 1 diabetes mellitus is often associated with autoimmune diseases. Thus, there has been 
an increased prevalence of autoantibodies related to celiac disease and many other 
autoantibodies against endocrine and nonendocrine organs. Not infrequently, these diseases 
manifest themselves associated paucisymptomatic and are diagnosed late. Despite this 
apparent relationship between type 1 diabetes mellitus and these autoimmune diseases has 
not been shown that the degree of glycemic control influence the likelihood of developing or 
subsequent developments. We must not forget that many of these clinical situations produce 
per se a decrease in the expectancy and quality of life of patients, another reason to actively 
pursue and establish treatment as soon as detected. 
Autoantibodies can be found in up to 25% of children and adolescents with diabetes, but 
only 3-5% have hypothyroidism. Hyperthyroidism is less common, but more often than 
children without diabetes. 
Autoimmune hypothyroidism may be associated with goitre (Hashimoto's thyroiditis or 
goiter), or in later stages of the disease, minimal residual thyroid tissue (atrophic 
thyroiditis). Because the autoimmune process gradually reduces thyroid function, there is a 
compensatory phase during which thyroid hormone levels are maintained by an elevated 
TSH. 
Although some patients may have mild symptoms, this phase is called subclinical or mild 
hypothyroidism. Later, T4 levels fall and TSH levels increase even more, the symptoms 
become more obvious at this stage (usually TSH> 10 mU/L) is called clinical 
hypothyroidism. 
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In Hashimoto's thyroiditis, there is a marked lymphocytic infiltration of the thyroid with 
germinal center formation, atrophy of thyroid follicles accompanied by oxyphil metaplasia, 
absence of colloid and mild or moderate fibrosis. As with most autoimmune disorders, 
susceptibility to this type of hypothyroidism depends on a combination of genetic and 
environmental factors and is increased sibling risk of autoimmune hypothyroidism or 
Graves disease. 
Genetic risk factors for this type of hypothyroidism in subjects caucasians are HLA-DR 
polymorphisms, specifically the HLA-DR3, HLA-DR4 and HLA-DR5. There is also a weak 
relationship between polymorphism of CTLA-4, a gene regulating T cells and autoimmune 
hypothyroidism. HLA-DR polymorphisms and CTLA-4 constitute about half of cases 
hipotiroidsimo autoimmune susceptibility. It is still necessary to identify other contributing 
loci. A gene located on chromosome 21 could be the cause of the relationship between 
autoimmune hypothyroidism and Down syndrome. 
The lymphocytic infiltrate thyroid autoimmune hypothyroidism is composed of CD4+ T 
cells and activated CD8+ and B cells. It is believed that the destruction of thyroid cells is 
mediated in a primary CD8+ T cells cytotoxic, which destroy their targets by perforin that 
cause cellular necrosis or through granzyme B, which induces apoptosis. 
Addition, cytokine production by local T cells, such as tumor necrosis factor, IL-1 and 
interferon gamma, can return to thyroid cells more susceptible to apoptosis mediated by 
death receptors such as Fas, which activate their ligands respective T cellIn addition, these 
cytokines directly disrupt the function of thyroid cells, and induce the expression of other 
proinflammatory molecules by thyroid cells themselves, such as cytokines, molecules of 
HLA class I and II, adhesion molecules, CD40 and nitric oxide. 
The administration of high concentrations for therapeutic cytokines (notably IFN alpha) is 
associated with enhancement of autoimmune thyroid disease, possibly by mechanisms 
similar to those involved in sporadic disease. 
The Tg and TPO antibodies are markers of thyroid autoimmunity with clinical utility, but 
their pathogenic effect is limited to a secondary role in the amplification of a developing 
immune response. TPO antibodies fix complement and are complex to the complement 
membrane attack the thyroid gland in case of autoimmune hypothyroidism. However, the 
transplacental passage of anti-Tg antibodies or anti-TPO has no effect on fetal thyroid gland, 
indicating that it takes an injury mediated by T cells to initiate autoimmune injury of the 
gland. 
Although it has been associated with the presence of subclinical hypothyroidism with an 
increased risk of symptomatic hypoglycemia and hipocrecimiento, it is quite common for 
thyroid dysfunction clinically pass unnoticed, so you must determine the levels of 
thyrotropic hormone (TSH) annually in those without autoantibodies or more often if there 
are or the patient has any symptoms. 
Celiac disease is 10 times more common in diabetics than in the general population and 
may affect up to 1-10% of diabetic patients. Also known as celiac sprue or gluten sensitive 
enteropathy is an autoimmune disorder triggered by ingestion of gliadin fractions present 
in the gluten and similar proteins of rye and barley in genetically predisposed 
individuals. 
Gluten is the main protein component of wheat, rye and barley. In celiac disease is triggered 
by an immune reaction that leads to inflammation of the small intestine mediated by T 
lymphocytes, with the development of hyperplastic crypts, intraepithelial lymphocytes and 
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villous atrophy, causing a chronic enteropathy with a broad range of manifestations, which 
make a systemic disease of varying severity. 
Adherence to a gluten-free diet is followed by clinical and histological improvement in these 
patients, with normalization of long-term intestinal architecture, and the property of the 
recurrence of symptoms when gluten is reintroduced in the diet . 
The presence of an immune component in the etiology of the disease was suspected for 
three reasons. First, no serum IgA antigliadin antibodies and endomysial, although it is 
unclear whether primary or secondary to tissue injury. Endomysial antibody has a 
sensitivity of 90 and specificity 95%, and its antigen is tissue transglutaminase. Secondly, 
treatment with prednisolone for four weeks in a celiac patient who continues to eat gluten 
induces remission and duodenal epithelium gives a more normal level. Finally, the gliadin 
peptides interact with gliadin-specific T cells, which in turn can act as mediators of tissue 
injury or cause the release of one or more cytokines that are responsible for tissue injury. 
In celiac disease are also implicated genetic factors, its incidence varies widely among 
different population groups (high in Caucasians and low in color and eastern race) and is 
10% in first degree relatives of patients with celiac disease. In addition, about 95% of celiac 
patients express the allele of the human leukocyte antigen DQ2, whereas only a minority of 
all people who express DQ2 have celiac disease. 
Not forget that the diagnosis of celiac disease is made by biopsy of the small intestine. Is 
performed on patients with symptoms and laboratory findings suggestive of malabsorption 
or lack of nutrients. 
Is often asymptomatic, but can cause gastrointestinal symptoms, short stature and anemia. 
This condition is also associated with an increased number of hypoglycemic episodes and a 
progressive decrease in insulin requirements in the year prior to diagnosis. It is also 
recommended measuring endomysial or tissue transglutaminase after diagnosis and every 
2-3 years in post, in asymptomatic patients or whenever there is clinical suspicion, given the 
possibility of seroconversion over time in some patientsin which antibodies were initially 
detected. 
Addison's disease, another autoimmune disease is present up to 2% of type 1 diabetes 
presenting autoantibodies against the enzyme 21-hydroxylase and the enzyme cleavage of 
the side chain, but it ignores the importance of these antincuerpos in the pathogenesis 
ofadrenal insufficiency. Some antibodies cause adrenal insufficiency by blocking the binding 
of ACTH to its receptors. 
The appearance of two or more of these autoimmune endocrine same person characterized 
in a polyglandular autoimmune syndrome type II (thyroid, parathyroid and gonadal tissue), 
this syndrome has yet mutated gene on chromosome 6 and is associated with alleles B8 and 
HLA DR3. 
The presence of adrenal insufficiency is rare, so it is recommended not look systematically. 
In addition to the classic symptoms for adrenal insufficiency are at risk of frequent 
hypoglycemia and reduced daily insulin requirements. 
The 15-20% of adults have diabetes autoimmune gastropathy presenting autoantibodies to 
gastric parietal cells, and 50% have clinical or pathological signs of atrophic gastritis. Yet 
there are no recommendations regarding the detection of these antibodies, given the lower 
prevalence in childhood. 
With respect to autoimmune diseases of the skin, vitiligo has been found up to 7% of 
children and adolescents with type 1 diabetes mellitus. 
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The objectives of this study are the following: make an epidemiological study of type 1 
diabetes mellitus in childhood and adolescence, to study the HLA-DQ genetic group and 
general parameters in the onset of the disease, and the pursuit of development of 
autoimmune diseases. 
Today diabetes education is fundamental and essential, in consultation diabetes control 
emphasizes good glycemic control in order to reduce microvascular complications, rare in 
children because their development is in adulthood. It also reports on the association with 
microvascular problems such as diabetic retinopathy, microalbuminuria leading to 
nephropathy, and diabetic neuropathy, as well as on macrovascular problems such as 
atherosclerosis. 
Are known to coexist in these patients, with chronic hyperglycemia in cardiovascular risk 
otrosfactores. Diabetes education programs and health promotion should report on the 
harmful effects of some of them, such as smoking, overweight or sedentary. We should not 
forget the high prevalence of these diseases justifies the systematic implementation of its 
screening in the units of pediatric endocrinology. The early diagnosis of these can improve 
the control of type 1 diabetes mellitus. 
2. Patient and methods 
This study was carried out at the Department of Pediatrics, General Hospital of Ciudad 
Real. This work is a descriptive epidemiological study on 129 children and adolescents 
under age 16 with type 1 diabetes mellitus, studied in this hospital since 1990. With regard 
to epidemiological studies by our group in the province of Ciudad Real, with an estimated 
total of 423 patients with DM1, of which 204 are under 16 years, the size of the sample 
makes it representative of the distribution of type 1 diabetes mellitus population. 
The analysis began in January 2003 starting with a retrospective study of patients and 
performing a 3-year prospective follow-up on these patients and patients who were going to 
the Department of Pediatrics at the start of his diabetes. The analysis and recruitment was 
completed in December 2007. This study was approved by the Research and Ethics 
Committee of the General Hospital of Ciudad Real. Reported and informed consent was 
obtained from parents or guardians. 
In our study we asked whether there is a relationship between the occurrence of 
autoimmune diseases in pediatric patients with type 1 diabetes mellitus, with the HLA-DQ 
genetic group. Main objective genetic group analyzed HLA-DQ by molecular biology of our 
patients. According to these HLA-DQ haplotypes have organized groups I, II and III, 
considered by the usual bibliography and diabetogenic risk. 
 Group I: HLA-DQA1*0501/DQB1*0201 
 Group II: HLA-DQA1*0301/DQB1*0302 
 Group III: HLA-DQA1*0501,*0301/HLA-DQB1*0201,*0302 
 Group IV: No genetic group associated with DM1 
As secondary objectives we analyzed the disease onset general parameters such as sex and 
age. We collected data on whether patients had autoimmune disease associated with type 
1 diabetes mellitus, if the onset of the disease has been before or after the debut of type 1 
diabetes mellitus and the median time to onset of the disease. These parameters are 
studied during a follow-up period of 3 years with updates every 6 months. All of these 
secondary objectives relate them to the diabetogenic risk group assigned to each of our 
patients. 
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The degree of innovation under our study was that the determination of HLA-DQ alleles 
was performed by molecular biology techniques, to avoid large differences, about 50% 
errors (58% according to the results of our group), which are generated if only theserological 
determinations. HLA-DQ alleles were determined by reaction polymerase chain, with allele 
specific amplification (PCR-SSP). We used specific primers for DQA1 and DQB1 genes 
(Protrans, Ger.) Amplified products were separated by agarose gel electrophoresis in 2% 
and were assigned allele specific amplification. 
Determinations of antithyroid antibodies, and antithyroglobulin antimicrosomal performed 
by chemiluminescence, IMMULITE 2000 (Dipesa ®). Thyroid hormones: T4 and TSH by 
chemiluminescent immunoassay technology microparticles, ARCHITECT (Abbott ®). 
As serologic marker in detecting celiac disease transglutaminase antibodies were analyzed 
by enzyme immunoassay with recombinant human tissue transglutaminase (Eurospital ®) 
with a sensitivity around 95% and a specificity above 95% for populationspediatric. Patients 
with positive markers underwent a biopsy of the duodenum and subsequent intestinal 
pathology. 
For the analysis of the data is first created a database with Microsoft Access and have 
subsequently be exported for statistical analysis by SPSS for Windows, version 12.0. We 
conducted a 6x4 design. Each patient was studied in 6 different moments of its evolution, 
with 4 viable possibilities, different genetic risk groups.  
Study possible changes in the variables under study during the monitoring period, if the 
changes are influenced by risk group HLA-DQ, and if it influenced other control variables 
such as sex, age, etc. All statistical tests were performed with a significance level of 95% and 
an alpha of 0.05%. 
2.1 Results 
According to the HLA-DQ haplotypes obtained, the distribution of diabetogenic risk groups 
was as follows: group I (HLA-DQA1*0501/DQB1*0201): 45 patients, accounting for 34.9%, 
group II (HLA-DQA1*0301/DQB1*0302): 38 patients, representing 29.5%, group III (HLA-
DQA1*0501,*0301/HLA-DQB1*0201,*0302): 38 patients, representing 29.5%, and group IV 
(no gene associated with DM1 group): 8 patients, representing 6, 2% (Figure 1). 
 
 
Fig. 1. HLA-DQ Diabetogenic risk groups 
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The gender distribution of our study population of 129 patients was as follows: males 67 
patients representing 51.9% and women 62 patients representing 48.1%, with a ratio child of 
1,08. 
The distribution of patients by age at onset was as follows: 0 to 4 years 32 patients 
representing 24.8%, between 5 and 9 years 67 patients, representing 51.9%, between 10 and 
14 years 29 patients who account for 22.4% and between 15 and 16 years 1 patientrepresents 
0.8%. The mean age of patients, whose mean values (mean ± SD), expressed in years, 
diabetogenic risk groups were as follows: Group I (8.6 ± 3.4), Group II (7 ± 3), Group III (6.1 
± 2.7) and Group IV (6.8 ± 2.6). In our study found significant differences in age at debut by 
diabetogenic risk groups, age at onset being significantly lower in group III with group I 
(Figure 2). 
 
 
Fig. 2. Distribution of patients by age at onset 
The incidence of patients with autoimmune thyroiditis in our series is 15.5%, representing a 
total of 20 patients. At the time of diagnosis of thyroiditis, 85% were euthyroid autoimmune 
thyroiditis and 15% had undergone an underactive thyroid. In the euthyroid, 17.6% (n = 3) 
associated with thyroid hypofunction later. 
The sex distribution is as follows: 55% (n = 11) were women and 45% (n = 9) were male. No 
significant differences were observed in the distribution of autoimmune thyroiditis by sex. 
Distribution diabetogenic risk groups was as follows: Group I: 6 patients, Group II: 5 
patients, Group III: 8 patients, and Group IV: 1 patient. No significant differences were 
found in the diagnosis of autoimmune thyroiditis diabetogenic risk groups (Figure 3). 
When analyzing patients with autoimmune thyroiditis, it was observed that 76.4% started 
after the debut of type 1 diabetes mellitus, whereas 23.6% were diagnosed simultaneously 
with the debut of it. By contrast patients with underactive thyroiditis, 28.6% presented prior 
to the commencement of type 1 diabetes mellitus, 42.8% thereafter, and 28.6% to debut 
simultaneously do the same. 
In our series we found a case of hyperthyroidism in a 11-year-old was diagnosed with type 
1 diabetes three years ago. The frequency of patients with celiac disease associated with type 
1 diabetes mellitus in our series is 6.2%, which corresponds to 8 patients. The sex 
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distribution is as follows: 75% (n = 6) are women and 25% (n = 2) are male. We found 
significant differences in favor of women (p <0.001). 
 
 
Fig. 3. Autoimmune thyroiditis by diabetogenic risk groups 
Distribution diabetogenic risk groups was as follows: Group I: 2 patients, Group II: 2 
patients, Group III: 3 patients, and Group IV: 1 patient. No significant differences were 
found in the diagnosis of celiac disease by diabetogenic risk groups (Figure 4). 
 
 
Fig. 4. Celiac disease by diabetogenic risk groups 
As for the timing of the debut has been observed that in 75% (n = 6), the debut of celiac 
disease after debut of type 1 diabetes mellitus, and 25% (n = 2) the onset is earlier. In most 
cases of celiac disease were asymptomatic at diagnosis and only observed the existence of 
signs of malabsorption in 1 patient, abdominal distention and diarrhea. The average time 
between debut and diagnosis was 22 months with a minimum of 6 months and a maximum 
of 34 months. 
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In our series, 2 patients are associated with type 1 diabetes mellitus, celiac disease and 
autoimmune thyroiditis (1 patient 1 patient euthyroid and hypothyroid). 
In 13 patients (10.1%) were type allergic processes associated allergic rhinitis and 
conjunctivitis, 8 patients (6.2%) had asthma, 8 patients (6.2%) were diagnosed with atopic 
dermatitis and 1 patient ( 0.7%) of vitiligo. 
2.1.1 Discussion 
In type 1 diabetes mellitus there is a polygenic susceptibility. The most important genes that 
influence human susceptibility to type 1 diabetes mellitus are located in the complex HLA 
class II. In our series, these data are corroborated, and that these associations are most 
common. 93.8% of our patients with type 1 diabetes mellitus corresponds to the genetic risk 
groups as has been described elsewhere, so a 6.2% suffer from type 1 diabetes mellitus 
without belonging to a group of HLA-DQ risk. 
Our results agree with others, as published by the EURODIAB indicating that in most 
mediterranean countries the male/female ratio is around 1, with a slight male 
predominance, but with no significant differences between them. 
The period of highest incidence in the study is between 5 and 9 years. These findings are 
consistent with studies in other countries, which show a tendency for the disease much 
earlier debut. In our study found significant differences in age at debut by diabetogenic risk 
groups, age at onset being significantly lower in group III with group I. These results 
indicate that the combination of different molecules in susceptibility, heterozygous in group 
III, accelerating the destruction of beta cells by promoting an early onset of type 1 diabetes 
mellitus. 
Autoimmune disease most often associated to type 1 diabetes mellitus is an autoimmune 
thyroid disease. Our results, 15.5% compared to the percentage of subjects who agree 
thyroiditis associated with many studies, such as in Spain by Roland and cols (1999) or 
made in Italy by Lorini and cols (1996). However, some international studies show higher 
prevalence, such as that conducted by Lindberg et al (1997), with a prevalence of 38%. 
As in other studies in our series of cases in which thyroiditis manifested clinically, it is in the 
form of an underactive thyroid. Although thyroid status of the majority of subjects with 
positive markers is euthyroid. 
In our series we found a case of hyperthyroidism in a 11-year-old was diagnosed with type 
1 diabetes three years ago. Hyperthyroidism is associated with type 1 diabetes mellitus 
present in 1% of cases, most often in adults. Other studies indicate that hyperthyroidism is 
usually diagnosed before or while type 1 diabetes mellitus. 
Studies show that thyroiditis is more prevalent in diabetic girls than in boys. However, our 
results do not indicate such a difference, matching other studies. 
The prevalence of celiac disease associated with children with type 1 diabetes mellitus varies 
between 1-16%. In our series, we found a total of 8 patients under 6.2% of all patients. These 
results are consistent with those of Vitoria et al. However, some studies show minor 
incidents, such as by Barera and colleagues (2002) with a prevalence of 3.9%. In some other 
series have reported higher frequencies, between 8 and 12.3%. 
As for the timing of the debut our results coincide with those published by Barera et al, and 
Holmes et al (2002), in which the majority of patients the diagnosis of celiac disease is 
posterior to that of type 1 diabetes mellitus. The time elapsed since the debut of the type 1 
diabetes mellitus and identification of antibodies in our series are consistent with the results 
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of Saukkonen et al (1996), which are located around the 2 years following the onset of type 1 
diabetes mellitus. Other studies such as Maki and colleagues (1995), who observed a lower 
average interval around 13 months. Our results on the significant association in women are 
endorsed by other studies in this regard, as published in Spain by Roldan et al (1998). 
Most patients were asymptomatic at the time of his presentation and noted that there were 
no signs of frank malnutrition. Were diagnosed by serological screening and subsequent 
confirmation with intestinal biopsy. Our results are consistent with those of Barrera et al. 
Not found in our series more partnerships with other autoimmune diseases such as 
pernicious anemia, Addison's disease, Sjögren syndrome, alopecia areata, and rheumatoid 
arthritis. 
Among the background approximately 10% of the patients had atopy and bronchial asthma. 
These data are consistent with those reported by Lopez Medina et al in their series. The 
presence of vitiligo in our series (0.7%) is lower than that observed in other studies like the 
one made in Italy by Romano et al (1998), showing a prevalence of 9%. 
3. Conclusion 
The major autoimmune diseases, autoimmune thyroiditis and celiac disease are more 
prevalent in our diabetic patients than in the nondiabetic population. Although we found 
more patients in risk group III, no significant differences with other groups. 
In conclusion, these data support the recommendation that from the moment of diagnosis of 
type 1 diabetes mellitus regular determination of thyroid antibodies and celiac disease 
related. Current recommendations are vague as to what should be the most appropriate 
timing for this in pediatric patients. We must try to detect such diseases early, but that does 
not justify excessive and unnecessary repetition of diagnostic tests. The use of standardized 
monitoring protocols is becoming increasingly necessary to ensure better health care for 
children and adolescents with type 1 diabetes mellitus. 
4. References 
Green, A.; Gale, EA. & Patterson, CC for the EURODIAB ACE Study Group (1992) Incidence 
of childhood-onset insulin-dependent diabetes mellitus: the EURODIAB ACE 
study. Lancet 1992; 339: 905-909. 
Roldan, MB.; Alonso M.; Barrio R.; (1999) Thyroid autoimmunity in children and 
adolescents with type 1 diabetes mellitus. Diabetes Nutr Metab 1999; 12:27–31. 
Lorini, R; Scaramuzza, A; Vitali, L; d’Annunzio,  G; Avanzini, MA; De Giacomo, C et al. 
(1996) Clinical aspects of celiac disease in children with insulin-dependent diabetes 
mellitus. J Pediatr Endocrinol Metab 1996;(Suppl 1):101-11. 
Lindberg, B.; Ericsson, UB.; Ljung, R.; (1997) High prevalence of thyroid autoantibodies at 
diagnosis of insulin-dependent diabetes mellitus in Sweden children. J Lab Clin Med 
1997; 130: 585-589. 
Holmes GTK. (2002). Screening for coeliac disease in type 1 diabetes. Arch Dis Child 
2002;87:495-8. 
Barera, G.; Bonfanti, R.; Viscardi, M et al.(2002) Ocurrence of celiac disease alter onset of 
type 1 diabetes: a six-year prospective longitudinal study. Pediatrics 2002; 109: 261-
267. 
www.intechopen.com
  
Type 1 Diabetes Complications 
 
154 
Romano, G.; Moretti, G.; Di Benedetto, A.; Ruso, G et al. (1998) Skin lesion in diabetes 
mellitus: prevalence and clinical correlations. Diabetes Res Clin Pract 1998; 39(2): 
101-106. 
Saukkonen, T.; Savilahti, E.; Reijonen, H.; Ilonen, J.; Tuomilehto-Wolf, E.; Akerblom, HK. 
(1996) Celiac disease: Frequent occurrence after clinical onset of insulin-dependent 
diabetes mellitus: Childhood Diabetes in Finland Study Group. Diabet Med 1996; 
13:464-70. 
Maki, M.; Holm, K.; Hallstrom, O.; (1995) Seroconversion of reticulin autoahmtibodies 
predios coeliac disease in insulin dependent diabetes mellitus. Gut 1995; 36: 239-42. 
Roldan, MB.; Barrio, R.; Roy, G.; Parra, C.; Alonso, M et al. (1998) Diagnostic value of 
serological markers for celiac disease in diabetic children and adolescent. J Pediatr 
Endocrinol Metab 1998; 11: 751-756. 
www.intechopen.com
Type 1 Diabetes Complications
Edited by Prof. David Wagner
ISBN 978-953-307-788-8
Hard cover, 482 pages
Publisher InTech
Published online 25, November, 2011
Published in print edition November, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
This book is a compilation of reviews about the complication of Type 1 Diabetes. T1D is a classic autoimmune
disease. Genetic factors are clearly determinant but cannot explain the rapid, even overwhelming expanse of
this disease. Understanding etiology and pathogenesis of this disease is essential. The complications
associated with T1D cover a range of clinical obstacles. A number of experts in the field have covered a range
of topics for consideration that are applicable to researcher and clinician alike. This book provides apt
descriptions of cutting edge technologies and applications in the ever going search for treatments and cure for
diabetes.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
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